Analysis of Long Non-coding RNAs in Stroke

Long non-coding RNAs (LncRNAs) are non-protein coding transcripts capable of regulating cellular processes and gene expression. LncRNAs are highly expressed in the brain and have been extensively studied for their roles in neurodevelopment and neurological disorders. Hundreds of lncRNAs have been found to be aberrantly expressed after stroke in human and rodent experimental stroke models, and these lncRNAs are thought to promote apoptosis, angiogenesis, inflammation, and cell death. In addition, lncRNAs have been evaluated as potential diagnostic and prognostic biomarkers in stroke and pathophysiological mediators in rodent models of ischemic and hemorrhagic stroke.

Fig. 1. Therapeutic and diagnostic tools based on lncRNA provide a very attractive area of research in stroke.Fig. 1. LncRNAs as promising therapeutic approach in ischemic stroke. (Wolska et al., 2021)

Our Analysis Services for LncRNAs in Stroke

Ace Therapeutics provides reliable services to analyze the function and mechanism of lncRNAs in ischemic stroke and help clients identify novel therapeutic targets for stroke. We utilize high-throughput sequencing, advanced bioinformatics tools, and experimental validation studies to ensure the highest quality analysis for our clients.

We provide in vitro and in vivo stroke models to confirm the functional significance of specific lncRNAs in stroke. Through rigorous bioinformatics analysis, we can compare lncRNA expression profiles between stroke-affected and healthy tissues. We also help our clients develop potential biomarkers for stroke diagnosis and prognosis as well as for monitoring treatment response by identifying dysregulated lncRNAs.

Transcriptome Analysis

We utilize RNA-seq and microarray technologies to comprehensively analyze the transcriptomes of ischemic injury animals and healthy controls, helping clients to discover and characterize stroke-related differentially expressed lncRNAs, including antisense non-coding RNA (ANRIL) in the INK4 locus, metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), N1LR, maternally expressed gene 3 (MEG3), H19 (MEG3), H19, CaMK2D-related transcript 1 (C2dat1), Fos downstream transcript (FosDT), small nuclear kernel RNA host gene 14 (SNHG14), and taurine up-regulated gene 1 (TUG1).

Expression Analysis of LncRNA

We use qRT-PCR, Northern blot, in situ hybridization and other techniques to detect the expression levels of specific lncRNAs known to be associated with stroke.

Functional Validation Experiments

By interfering with or overexpressing the target lncRNAs, we can analyze and observe the effects of stroke drugs on cells or animal stroke models. This includes detecting changes in cell proliferation, apoptosis, migration, inflammatory response, and other indicators.

Gene Ontology (GO) Enrichment Analysis

We provide GO enrichment analysis to predict the more functional and mechanistic aspects of these lncRNAs, such as MEG3, H19, MALAT1. We aim to provide data support to help clients better understand the functions and mechanisms of lncRNAs in ischemic stroke.

Ace Therapeutics helps clients to comprehensively elucidate the role of lncRNAs in the pathogenesis of stroke and to develop new targets for stroke diagnosis and treatment. If you are interested in our services, please do not hesitate to contact us!

  1. Wolska, M., et al. (2021). Long non-coding RNAs as promising therapeutic approach in ischemic stroke: a comprehensive review. Molecular Neurobiology, 58, 1664-1682.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Inquiry Basket